No way! But... [Design Issues]

posted by wienui  – Germany/Oman, 2019-12-07 05:01 (1147 d 16:28 ago) – Posting: # 20955
Views: 5,435

(edited by wienui on 2019-12-07 06:47)

Dear all,

❝ So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)


I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
22,477 posts in 4,708 threads, 1,603 registered users;
23 visitors (0 registered, 23 guests [including 7 identified bots]).
Forum time: 21:29 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5